|Mr. Sharon Malka CPA, MBA||Chief Exec. Officer||528k||N/A||1972|
|Prof. Lior Rosenberg||Co-Founder & Chief Medical Technology Officer||405k||N/A||1946|
|Mr. Carsten Henke||Chief Commercial Officer of Europe||338k||N/A||1966|
|Dr. Ety Klinger||Chief R&D Officer||350k||N/A||1962|
|Mr. Stephen T. Wills CPA, CPA, MST||Exec. Chairman||N/A||N/A||1957|
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.